$SANA News

Sana Biotechnolog Publishes Peer-Reviewed Letter To Editor In New England Journal Of Medicine

Sana Biotechnology To Present Data From Allogeneic Primary Islet Cell Therapy At European Association For The Study Of Diabetes

Sana Biotechnology, Inc. (SANA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Sana Biotechnology to Present at June 2026 Investor Conferences

Sana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market (ATM) Facility

Sana Biotechnology Announces Aggregate Sales Of 21,607,878 Shares With Net Proceeds Of ~$69M Through Its ATM Facility Established With TD Securities

Sana Biotechnology, Inc. (SANA) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Sana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPs

Sana Biotechnology Presents Preclinical Data Showing Surrogate SG293 Achieves Cell-Specific Delivery, Dose-Dependent CAR T Cell Generation, And Deep B Cell Depletion In NHPs At ASGCT 2026 Annual Meeting

Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates

Sana Biotechnology Q1 Adj. EPS $(0.14) Beats $(0.17) Estimate

Sana Biotechnology to Present at the BofA Securities 2026 Healthcare Conference

Sana Biotechnology Announces Oral Presentation Highlighting Preclinical Data from in vivo CAR T SG293 at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting

Sana Biotechnology Announces Oral Presentation Highlighting Preclinical Data From SG293 In Vivo CAR T Product Candidate At American Society Of Gene & Cell Therapy 2026 Annual Meeting May 11-15

Sana Biotechnology Announces Oral Presentation Highlighting Preclinical Data From SG293 In Vivo CAR T Product Candidate At American Society Of Gene & Cell Therapy 2026 Annual Meeting May 11-15

Sana Biotech (SANA), Mayo Clinic Partner to Advance Cell Therapy for Type 1 Diabetes

Assessing Sana Biotechnology (SANA) Valuation After Mayo Clinic Partnership And Equity Investment

Wedbush Lifts PT on Sana Biotechnology (SANA) to $7 From $6

Sana Biotechnology: Mayo Clinic Deal A Positive Step On A Long Journey

Wedbush Maintains Outperform on Sana Biotechnology, Raises Price Target to $7